BMY · earnings call history
Bristol-Myers Squibb Q1 FY26 — Growth portfolio +9%, tracking to upper end of guidance
Read the briefBristol-Myers Squibb Q4 FY25 – Strong Growth Portfolio Performance and Robust Pipeline Catalysts
Read the briefBristol-Myers Squibb Q3 FY25 — Strong Growth Portfolio Performance and Pipeline Advancement
Read the briefBristol-Myers Squibb Q1 FY25 — Strong Growth Portfolio Performance and Raised Full-Year Guidance
Read the briefBristol-Myers Squibb Q4 FY24 — Strong Growth Portfolio & Accelerated Pipeline
Read the briefBrowse all US companies on the earnings-call register.